HPV 相關疾病治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032 年

HPV Associated Disorders Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月30日 | 出版商:

Global Market Insights Inc. | 英文 235 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

受 HPV 相關癌症盛行率上升以及診斷技術進步的推動，2023 年全球 HPV 相關疾病治療市場規模為 196 億美元，2024 年至 2032 年複合年成長率將達到 4.9%。隨著人們對 HPV 與各種癌症之間關聯的認知不斷提高，越來越多的人尋求檢測和治療方案。診斷工具的創新提高了 HPV 檢測的準確性和速度，從而可以進行早期干預。人們對 HPV 相關疾病的預防和有效管理的日益關注可能會增加對標靶治療和篩檢計劃的需求，進一步推動市場成長。

HPV 相關疾病治療行業疾病類型、治療類型、最終用途和區域。

由於導致子宮頸上皮內瘤 (CIN) 的高盛行率，子宮頸上皮內瘤 (CIN) 領域的銷售額在 2023 年達到 61 億美元。隨著人們對疾病的認知不斷增強，對有效篩檢和治療方案的需求也不斷增加。診斷技術的進步可以實現早期檢測和干涉，從而改善患者的治療結果。此外，疫苗等標靶治療和預防措施的出現，進一步增強了對 CIN 管理的關注，鞏固了其在市場上的主導地位。

2023 年，藥物細分市場的佔有率達到 68.3%，這主要是由於有效的抗病毒療法和 HPV 相關疾病的治療方法越來越多。隨著人們對 HPV 對健康影響的認知不斷增強，患者正在尋求醫療解決方案來管理和治療相關疾病。藥物配方的創新，包括標靶治療和免疫療法，提高了治療效果。此外，新藥物和聯合療法的持續開發將推動市場成長，鞏固藥物領域的突出地位。

在對 HPV 相關健康問題的高度認知和強大的醫療基礎設施的推動下，北美將以 4.5% 的複合年成長率成長，到 2032 年將達到 133 億美元。該地區受益於先進的診斷技術和廣泛的治療選擇，包括疫苗和藥物。旨在提高疫苗接種率和早期檢測的公共衛生措施進一步支持市場成長。此外，對創新療法研發的大量投資有助於創造一個繁榮的市場環境，使北美成為 HPV 治療選擇全面擴展的關鍵貢獻者。

產業生態系統分析
產業影響力
- 成長動力
  - HPV 感染盛行率增加
  - 診斷技術的進步
  - 提高意識和教育
- 產業陷阱與挑戰
  - 疫苗和治療費用高昂
  - 副作用和安全問題
成長潛力分析
監管環境
未來市場趨勢
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按疾病類型，2021 - 2032

主要趨勢
子宮頸上皮內瘤（CIN）
子宮頸癌
肛門上皮內瘤 (AIN)
肛門癌
尖圭濕疣
其他疾病類型

第 6 章：市場估計與預測：按治療類型，2021 - 2032 年

主要趨勢
藥物
- 疫苗
- 抗病毒藥物
- 其他藥物
手術
- 冷凍療法
- 雷射手術
- 其他手術類型

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
門診手術中心
專科診所
其他最終用戶

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Biocon Ltd.
Bristol-Myers Squibb Company
Cleveland Clinic
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Hologic, Inc.
INOVIO Pharmaceuticals
Johnson and Johnson Services Inc. (Janssen Pharmaceutical)
Mayo Foundation for Medical Education and Research (MFMER).
Memorial Sloan Kettering Cancer Center
Merck and Co., Inc.
Pfizer, Inc.
The Johns Hopkins Hospital
Thermo Fisher Scientific Inc.

簡介目錄

Product Code: 11162

The Global HPV Associated Disorders Treatment Market, witnessed at USD 19.6 billion in 2023, will demonstrate a 4.9% CAGR between 2024 and 2032, spurred by the rising prevalence of HPV-related cancers, coupled with advancements in diagnostic technologies. As awareness of the link between HPV and various cancers increases, more individuals seek testing and treatment options. Innovations in diagnostic tools enhance the accuracy and speed of HPV detection, allowing for earlier interventions. This growing focus on prevention and effective management of HPV-related disorders is likely to boost the demand for targeted therapies and screening programs, further propelling market growth.

The HPV associated disorders treatment industry disease type, treatment type, end-use, and region.

The cervical intraepithelial neoplasia (CIN) segment achieved USD 6.1 billion in 2023, fueled by the high prevalence of HPV infections leading to CIN. As awareness of the condition grows, there is an increasing demand for effective screening and treatment options. Advances in diagnostic technologies allow for earlier detection and intervention, improving patient outcomes. Additionally, the availability of targeted therapies and preventive measures, such as vaccines, further enhances the focus on managing CIN, solidifying its dominant position in the market.

The medication segment secured 68.3% in 2023, primarily due to the increasing availability of effective antiviral therapies and treatments for HPV-related conditions. As awareness of HPV's impact on health grows, patients are seeking medical solutions to manage and treat associated disorders. Innovations in pharmaceutical formulations, including targeted therapies and immunotherapies, enhance treatment efficacy. Furthermore, the ongoing development of new medications and combination therapies will drive market growth, solidifying the medication segment's prominent position.

North America will grow at 4.5% CAGR to reach USD 13.3 billion by 2032, driven by high awareness of HPV-related health issues and robust healthcare infrastructure. The region benefits from advanced diagnostic technologies and a wide range of treatment options, including vaccines and medications. Public health initiatives aimed at increasing vaccination rates and early detection further support market growth. Also, significant investments in research and development for innovative therapies contribute to a thriving market environment, making North America a key contributor to the overall expansion of HPV treatment options.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of HPV infections
  - 3.2.1.2 Technological advancements in diagnostics
  - 3.2.1.3 Rising awareness and education
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of vaccines and treatments
  - 3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Cervical intraepithelial neoplasia (CIN)
5.3 Cervical cancer
5.4 Anal intraepithelial neoplasia (AIN)
5.5 Anal cancer
5.6 Genital warts
5.7 Other disease types

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Medication
- 6.2.1 Vaccines
- 6.2.2 Anti-viral drugs
- 6.2.3 Other medications
6.3 Surgery
- 6.3.1 Cryotherapy
- 6.3.2 Laser surgery
- 6.3.3 Other surgery types

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Specialty clinics
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa